Applicant, Authorized Representative and Importer Roles in Russia

1. Key takeaways

A foreign manufacturer cannot file a registration application with RZN in its own name. The compliant structure is built from three roles: the applicant (zayavitel, usually filled by the Russian authorized representative), the authorized representative of the manufacturer (upolnomochenny predstavitel izgotovitelya, UP), and the importer. The first two roles are required by registration law, while the importer is the operational actor in the circulation stage. Understanding which role carries which obligations, and documenting the boundaries between them, is a prerequisite for a stable Russian market presence.

The three roles may be combined in a single entity or held separately, and both arrangements are lawful. Combining them in one Russian partner creates efficiency, because one organization handles filings, correspondence, and goods movement with a single point of contact. Separating them creates resilience, because a change in one commercial relationship does not endanger the entire structure. Whichever arrangement is chosen, the allocation of duties must be written into contracts explicitly, since undocumented assumptions between the foreign manufacturer and its Russian partners are the most frequent source of disputes when problems arise later.

When choosing among these arrangements, manufacturers should start from the failure modes rather than from convenience. Ask what happens if the Russian partner stops answering; if the authorized representative resigns the role; if a shipment is stopped and the importer must respond within days. Each role carries duties that cannot wait for the foreign manufacturer to reorganize, and the contracts should say who performs those duties during a disruption. Written continuity provisions, successor arrangements for the authorized representative role, and pre-agreed data handover clauses cost little at signing and decide how much of the business survives a breakdown in the relationship.

2. Legal basis

3. Expert insights

Insight 1: The right to import and the right to register are two different things. According to the interpretation in Letter No. 01I-171/08, once a device is registered, any entity may import it; there is no qualification restriction at the import stage. This stands in instructive contrast to the authorized representative institution: the authorized representative is a mandatory figure in registration law, while the importer is simply a commercial arrangement. A manufacturer can therefore widen its distribution network freely without touching the registration file, provided the devices themselves remain within the registered scope and each importer meets its general obligations.

Insight 2: The duties of the authorized representative are continuous. The authorized representative details appear in the registration dossier and the register, and lapsed details trigger a suspension of 90 working days from September 1, 2027, followed by withdrawal if not cured. Replacing an authorized representative is therefore not like changing a supplier; it is a formal amendment procedure with statutory time limits, register updates, and consequences for lawfulness during the gap. Planning the transition with the full timeline in mind, and keeping the outgoing representative cooperative until the amendment is registered, protects continuity of circulation.

Insight 3: The three-in-one arrangement concentrates risk. Placing the applicant function, the representative function, and import into one Russian partner maximizes communication efficiency, but if the relationship changes, registration, inventory, and distribution are affected simultaneously. GRZAN usually recommends keeping at least two usable import channels open, so that a commercial dispute with one partner does not leave goods stranded or the market unsupplied while the registration structure remains untouched in the register.

4. Practical recommendations

1. Draft the power of attorney to cover the specific authority of circulation of medical devices within the territory of the Russian Federation, and attach a notarized Russian translation, so that both the registration authority and commercial partners see the same scope.
2. In distribution agreements, distinguish explicitly between a confirmation letter and an exclusive authorization, since overbroad exclusivity language can raise local antitrust compliance risks alongside ordinary commercial disputes.
3. Reserve the time required by the amendment procedure when replacing an authorized representative, and update labels and register information in sync, so that no period of inconsistency opens between the commercial change and the regulatory record.
4. Brief every importer on its notification obligations under Order No. 11020 as part of onboarding, so that the circulation chain carries the duty jointly rather than leaving it to assumption.

5. Verification checklist

• □ The identity of the applicant matches the registration dossier record
• □ The authorized representative power of attorney contains the specific circulation authority clause and a notarized Russian translation
• □ The authorized representative details have been updated before September 1, 2026
• □ There are two or more import channels, and each is familiar with the notification obligations of Order No. 11020
• □ The timing of the amendment procedure for replacing the representative has been built into the business continuity plan

GRZAN structures the applicant, authorized representative, and importer roles for foreign manufacturers in Russia, drafts powers of attorney with notarized Russian translations, manages authorized representative amendments within statutory deadlines, and designs resilient import channel arrangements that survive commercial changes. Our team keeps the three roles documented, separated where prudence requires, and aligned with Government Resolution No. 1684. For role structuring and RZN registration support in Russia, contact GRZAN at info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.